ChinaBio Partnering Forum ChinaBio LLC EBD Group ChinaBio Partnering Forum Image Map
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

ChinaBio® Partnering Forum 2015 Program Overview

www.ebdgroup.com/cbpf/program
Tuesday, April 14, 2015
13:30–17:20
Partnering Bootcamp: How to partner with global pharma more ►
Sponsored by:
Cooley LLPCooley LLP
17:30–19:30
ChinaBio® Partnering Forum Welcome Reception

All ChinaBio® Partnering Forum attendees are cordially invited to join us for the Welcome Reception.

Dome at Kerry Hotel, Pudong, Shanghai

Presented by:
BayHelixBayHelix

You will be able to pick up your name badge at the Welcome Reception.

Wednesday, April 15, 2015
08:00
Registration opens
08:00–09:00
Continental Breakfast
09:00–09:30
Welcome Remarks

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Greg B. Scott – President and Founder, ChinaBio® Group
ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:30–10:30
Keynote Panel
Western pharma's strategic role in China

Cross-border partnering and corporate investment activity are exploding in China, with many of the major pharma leading the way. But regulatory and compliance hurdles remain a challenge to multinational companies bringing their products to China. This dynamic environment is rapidly changing the role of Western pharma in China. On this keynote panel, senior executives from global pharma will examine how the rapidly changing landscape in China is driving their companies to adapt new research and development models to address the local market needs as well as the need for novel NMEs globally.

Moderator:
Greg B. Scott – President and Founder, ChinaBio® Group

Panelists:
  • Ajay Gautam, PhD, MBA – Executive Director and Head of Collaborations, AsiaPac and Emerging Markets, AstraZeneca
  • Hans Lindner, PhD – VP, Head of Global External Innovation and Alliances, Global Drug Discovery, Bayer HealthCare
  • Mark Noguchi – VP and Global Head, Alliance and Asset Management, Roche Partnering
  • Mingde Xia, PhD – Senior Director, Johnson & Johnson Innovation
ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30–11:00
Networking Break
10:30–17:00
One-to-one Meetings ►
11:00–12:00
Plenary Panel
Biologics: China's new wave of innovation

Moderator:
Steve Yang, PhD – Executive VP and COO, WuXi AppTec

Panelists:
  • Yuliang Huang, PhD – CEO, Generon (Shanghai) Corporation Ltd.
  • Scott Liu, PhD – President and CEO, Henlius Biotech Co., Ltd.
  • Peter Luo, PhD – Founder and CEO, Adagene (Suzhou) Limited
  • Joe Zhou, PhD – CEO, Genor BioPharma and VP, Walvax Group
ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:00–13:30
Luncheon
13:00–18:00 Company Presentations ►
13:30–14:30
Workshop
Regulatory and IP Workshop: Innovative biologics vs. biosimilars: Four questions for 2015

Speakers:
  • Katherine Wang, LLM – Partner, Ropes & Gray LLP
  • Geoffrey Lin, JD – Partner, Ropes & Gray LLP
ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:30–15:30
Workshop
In- and out-licensing in China: A guide to success

Chinese in- and out-licensing deals are jumping to new record levels every year. For small and medium-sized companies from the West, in-licensing assets to the Chinese market creates a great opportunity to enter this exciting market. Despite the lack of financial resources, bandwidth and regulatory expertise required for success in China, Western companies successfully navigate the process with the right partner.

For Chinese companies, the option to out-license their assets will create significant leverage with the Western life science industry and provides access to completely new networks. And yet despite all the upside and the excitement, many of the transactions never come to fruition or fail early on. This panel will discuss the dos and don'ts in the two-way licensing field and provide guidance to successful partnering.

Moderator:
Ruediger Hermann – Partner, Dechert LLP

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–16:00
Networking Break
16:00–17:00
Panel Discussion
Why VCs are pumping big money into China life science

2014 was a record year in VC investment in China with nearly USD 1.7 billion flowing into life science companies. Add to that, USD 1.4 billion in corporate investment, a total of USD 3.1 billion of cash flowed into early and mid-stage life science companies in China. What do VCs see in China that is attracting record amounts of capital, and why are they more active here than in traditional Western markets?

Moderator:
Greg B. Scott – President and Founder, ChinaBio® Group

Panelists:
  • Judith Li, MBA – Principal, Lilly Asia Ventures
  • Mark G. Lotter, MBA – Founder and CEO, Nuance Biotech Inc.
  • Jonathan Wang, PhD, MBA – Senior Managing Director, OrbiMed Asia
  • Michael Yu, PhD – President and CEO, Innovent Biologics, Inc.
ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:00–18:00
Exhibit Hall Champagne Reception
18:30–21:00
Gala Reception

Sponsored by:

Roche Roche

Thursday, April 16, 2015
08:00
Registration opens
08:00–09:00
Continental Breakfast
09:00–12:00 Company Presentations ►
09:00–16:00
One-to-one Meetings ►
09:00–10:45
Pharma company presentations
Johnson & Johnson Innovation

Johnson & Johnson Innovation
Thursday, 09:00–09:15

 

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:15–09:30
Roche

Roche
Thursday, 09:15–09:30

 

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:30–09:45
MSD

MSD
Thursday, 09:30–09:45

 

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Novo Nordisk A/S

Novo Nordisk A/S
Thursday, 09:45–10:00

 

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:00–10:15
Merck Serono

Merck Serono
Thursday, 10:00–10:15

 

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Boehringer Ingelheim Biopharmaceuticals (China) Ltd.

Boehringer Ingelheim Biopharmaceuticals (China) Ltd.
Thursday, 10:15–10:30

 

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30–10:45
AstraZeneca

AstraZeneca
Thursday, 10:30–10:45

 

ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:00–12:00
Panel Discussion
The top seven challenges in structuring China-related transactions

China is full of contradictions, and so is any transaction involving China. Whether you look at China as a source of capital or as a potential market, whether you are a Chinese company reaching out globally or an international company negotiating with a Chinese counterpart, the China factor looms large in your strategic planning and implementation activities. In this session, experts with significant cross-border transaction experience will share the top seven challenges they have faced in China and how these were resolved, and lead the discussion to help attendees learn how to analyze and resolve similar transactions.

Speakers:
  • Peter Corne, LLM – Managing Partner, Dorsey & Whitney LLP
  • Frank S. Hong, JD – Partner, Dorsey & Whitney LLP
ChinaBio® Partnering Forum 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:00–13:30
Luncheon
13:00–15:45 Company Presentations ►
15:30–17:00
Closing Reception
Arrow Up


© 2009–2015 EBD Group, Inc.
ChinaBio Partnering Forum ChinaBio LLC EBD Group ChinaBio Partnering Forum Image Map